- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00395317
Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)
April 5, 2012 updated by: GlaxoSmithKline
Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months Administration of SB-683699 in Subjects With Relapsing-Remitting Multiple Sclerosis
SB-683699 is an oral medication that is thought to reduce the number of active white blood cells entering the brain; these white blood cells are part of the disease process for MS.
This study will look at whether different doses of SB-683699 are effective and safe in patients with relapsing remitting MS.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
343
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- GSK Investigational Site
-
-
South Australia
-
Woodville, South Australia, Australia, 5011
- GSK Investigational Site
-
-
Victoria
-
Fitzroy, Victoria, Australia, 3065
- GSK Investigational Site
-
Parkville, Victoria, Australia, 3050
- GSK Investigational Site
-
-
-
-
-
Graz, Austria, A-8036
- GSK Investigational Site
-
Innsbruck, Austria, A-6020
- GSK Investigational Site
-
-
-
-
Ontario
-
London, Ontario, Canada, N6A 5C1
- GSK Investigational Site
-
Ottawa, Ontario, Canada, K1H 8L6
- GSK Investigational Site
-
-
Quebec
-
Gatineau, Quebec, Canada, J9J 0A5
- GSK Investigational Site
-
Greenfield Park, Quebec, Canada, J4V 2J2
- GSK Investigational Site
-
-
-
-
-
Turku, Finland, 20100
- GSK Investigational Site
-
-
-
-
-
Clermont Ferrand, France, 63003
- GSK Investigational Site
-
Dijon, France, 21033
- GSK Investigational Site
-
Lille, France, 59000
- GSK Investigational Site
-
Marseille, France, 13385
- GSK Investigational Site
-
Nantes, France, 44093
- GSK Investigational Site
-
Rennes Cedex 9, France, 35033
- GSK Investigational Site
-
Strasbourg, France, 67091
- GSK Investigational Site
-
-
-
-
-
Berlin, Germany, 10625
- GSK Investigational Site
-
Berlin, Germany, 10961
- GSK Investigational Site
-
Berlin, Germany, 12167
- GSK Investigational Site
-
Hamburg, Germany, 22087
- GSK Investigational Site
-
-
Bayern
-
Neuburg / Donau, Bayern, Germany, 86633
- GSK Investigational Site
-
-
Hessen
-
Herborn, Hessen, Germany, 35745
- GSK Investigational Site
-
-
Mecklenburg-Vorpommern
-
Rostock, Mecklenburg-Vorpommern, Germany, 18147
- GSK Investigational Site
-
-
Niedersachsen
-
Achim, Niedersachsen, Germany, 28832
- GSK Investigational Site
-
Hannover, Niedersachsen, Germany, 30625
- GSK Investigational Site
-
-
Nordrhein-Westfalen
-
Bad Honnef, Nordrhein-Westfalen, Germany, 53604
- GSK Investigational Site
-
Bielefeld, Nordrhein-Westfalen, Germany, 33647
- GSK Investigational Site
-
Dueren, Nordrhein-Westfalen, Germany, 52349
- GSK Investigational Site
-
Essen, Nordrhein-Westfalen, Germany, 45122
- GSK Investigational Site
-
Koeln, Nordrhein-Westfalen, Germany, 50767
- GSK Investigational Site
-
Koeln, Nordrhein-Westfalen, Germany, 51109
- GSK Investigational Site
-
-
Sachsen
-
Dresden, Sachsen, Germany, 01307
- GSK Investigational Site
-
Leipzig, Sachsen, Germany, 04103
- GSK Investigational Site
-
Leipzig, Sachsen, Germany, 04157
- GSK Investigational Site
-
-
-
-
Abruzzo
-
Chieti, Abruzzo, Italy, 66013
- GSK Investigational Site
-
-
Lazio
-
Roma, Lazio, Italy, 00163
- GSK Investigational Site
-
-
Lombardia
-
Gallarate, Lombardia, Italy, 21013
- GSK Investigational Site
-
Milano, Lombardia, Italy, 20132
- GSK Investigational Site
-
-
Toscana
-
Siena, Toscana, Italy, 53100
- GSK Investigational Site
-
-
-
-
-
Breda, Netherlands, 4818 CK
- GSK Investigational Site
-
Den Bosch, Netherlands, 5211 RW
- GSK Investigational Site
-
Eindhoven, Netherlands, 5623 EJ
- GSK Investigational Site
-
Nieuwegein, Netherlands, 3435 CM
- GSK Investigational Site
-
Sittard-geleen, Netherlands, 6162 BG
- GSK Investigational Site
-
Venray, Netherlands, 5801 CE
- GSK Investigational Site
-
-
-
-
-
Auckland, New Zealand, 1001
- GSK Investigational Site
-
Christchurch, New Zealand, 8001
- GSK Investigational Site
-
Wellington, New Zealand, 6021
- GSK Investigational Site
-
-
-
-
-
Bergen, Norway, 5021
- GSK Investigational Site
-
Drammen, Norway, 3004
- GSK Investigational Site
-
Hamar, Norway, 2317
- GSK Investigational Site
-
Sandnes, Norway, 4313
- GSK Investigational Site
-
Skien, Norway, 3710
- GSK Investigational Site
-
-
-
-
-
Gdansk, Poland, 80-299
- GSK Investigational Site
-
Poznan, Poland, 61-298
- GSK Investigational Site
-
Poznan, Poland, 60-479
- GSK Investigational Site
-
Warsaw, Poland, 02-097
- GSK Investigational Site
-
-
-
-
-
Moscow, Russian Federation, 125101
- GSK Investigational Site
-
Moscow, Russian Federation, 117049
- GSK Investigational Site
-
Moscow, Russian Federation, 125367
- GSK Investigational Site
-
St-Petersburg, Russian Federation, 194354
- GSK Investigational Site
-
St. Petersburg, Russian Federation, 197022
- GSK Investigational Site
-
St.-Petersburg, Russian Federation, 194291
- GSK Investigational Site
-
St.-Petersburg, Russian Federation, 197376
- GSK Investigational Site
-
-
-
-
-
Barakaldo (Vizcaya), Spain, 48903
- GSK Investigational Site
-
Barcelona, Spain, 08035
- GSK Investigational Site
-
Madrid, Spain, 28007
- GSK Investigational Site
-
Madrid, Spain, 28046
- GSK Investigational Site
-
Madrid, Spain, 28035
- GSK Investigational Site
-
San Sebastián, Spain, 20014
- GSK Investigational Site
-
Sevilla, Spain, 41071
- GSK Investigational Site
-
Valencia, Spain, 46010
- GSK Investigational Site
-
-
-
-
-
Hartshill, Stoke-on-Trent, United Kingdom, ST4 7LN
- GSK Investigational Site
-
Newcastle-Upon-Tyne, United Kingdom, NE1 4LP
- GSK Investigational Site
-
Nottingham, United Kingdom, NG7 2UH
- GSK Investigational Site
-
Sheffield, United Kingdom, S10 2JF
- GSK Investigational Site
-
-
Essex
-
Romford, Essex, United Kingdom, RM7 0AG
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
- Written informed consent
- Males or females, aged 18 to 65, inclusive
- A diagnosis of relapsing-remitting MS [Polman, 2005; McDonald, 2001] with dissemination in time and space
- EDSS of between 0 and 6.0 inclusive at the Screening visit
- Occurrence of at least two relapses in previous 24 months with at least one relapse or documented evidence of gadolinium-enhancement on MRI (prior to screening) in the previous 12 months. Subject must not have had a relapse within 4 weeks prior to Screening. In addition, subjects experiencing a relapse between Screen and Visit 3 will not be eligible to be randomized.
- A minimum of five T2 lesions on brain MRI at Visit 2 as determined by the central MRI analysis reader
A female subject is eligible to enter the study if she is:
- Of non-childbearing potential, i.e. women who:
- have documented evidence of tubal ligation, bilateral oophorectomy or hysterectomy; or
- are post-menopausal, defined as at least one year without menses in the absence of hormone replacement therapy. In questionable cases, menopausal status will be confirmed by oestradiol and FSH levels consistent with menopause according to local laboratory ranges. Oestrogen-containing hormone replacement therapies are not allowed during the study.
- Of childbearing potential, has a negative urine pregnancy test at Screening, and agrees to the consistent and correct use of one of the methods of contraception listed below. Subjects will use this contraceptive method for at least one month prior to Screening and should continue to use the same contraceptive method throughout the study until at least 3 days after the last dose of investigational product.
- Progesterone-only oral contraceptives or implants (inserted at least one month prior to Screening, but not beyond the third successive year following insertion). Oestrogen-containing contraceptives are not allowed during the study.
- Intra-uterine device (IUD) inserted by a qualified clinician. The IUD must have published data showing that the highest expected failure rate is less than 1% per year.
- Spermicide in conjunction with either a diaphragm, cervical cap or condom. Male partner sterilization (vasectomy) prior to female subject's entry into the study and is the sole partner for that female subject
- In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.
Exclusion Criteria:
- Subjects receiving corticosteroids within 4 weeks of Screening for treatment of MS. If non-systemic steroids are being used for other chronic inflammatory conditions, subjects may be included at the discretion of the investigator after discussion with the GSK medical monitor
- Use of an b-interferon product, glatiramer acetate or azathioprine within 3 months of Screening, or use of Mitoxantrone within 12 months of Screening. Subjects who have received other therapies affecting the immune system (such as intravenous immunoglobulin (IVIg), cyclophosphamide, plasmapheresis, or any other immunosuppressive or immunomodulatory treatment) in the past may be included on a case by case basis after discussion with the GSK medical monitor. None of these treatments will be allowed during this study
- Previous exposure to alemtuzumab, natalizumab or firategrast administration, bone marrow transplantation or whole body irradiation
- Subjects with a cardiac pacemaker or any other type of metal implant or with any other contraindication for MRI (including known allergy to gadolinium)
- Use of 4-aminopyridine, rosiglitazone, pioglitazone or any drug that is an inhibitor of or a substrate (with a low therapeutic index) for OATP at Screening.
- Subjects with clinically significant renal laboratory values: subjects with a calculated creatinine clearance <60ml/min (by Cockcroft and Gault) at Screening
- Subjects with local urinalysis findings of 1) proteinuria, defined as ≥1+ protein, on urine dipstick or 2) renal tubular cell casts or 3) ≥5 red blood cells / high power field will be excluded from the study if the result is still present on a repeat urinalysis during the screening period.
- Presence of clinically significant hepatic laboratory values: ALT, AST, GGT > 2.0- times the upper limit of normal (ULN); total bilirubin > 1.5 times the ULN at Screening
- CD4 count <500, CD4:CD8 <1.0 (if result still present on a repeat test during the screening period), JC viremia detected in plasma or white cells, idiopathic CD4/CD8 lymphopenia or secondary lymphopenia at Screening
- Any findings on the MRI of the brain at Visit 2 other than MS, except for benign findings that (in the opinion of the central MRI reading site and local site investigator) require no further evaluation or treatment and do not impact patient's neurological health (e.g., small arachnoid cysts, venous angiomas)
- Current or history of cancer, excluding localized non-melanoma skin cancer
- Uncontrolled or any active bacterial, viral, or fungal infection at Screening. Any previous serious infections should be discussed with the GSK medical monitor (e.g. opportunistic or atypical infections)
- History of tuberculosis (TB) or positive chest X-ray for TB at Screening (prior chest X-ray is acceptable if performed within previous 6 months)
- Known congenital or acquired immunodeficiency
- Any abnormality on 12-lead ECG at Screening which is clinically significant in the opinion of the investigator
- Subjects with positive hepatitis B surface antigen, hepatitis C antibody, or HIV tests at Screening
- Women who are lactating, pregnant (positive pregnancy test at Screening), or planning to become pregnant during the course of the study
- Recent history or suspicion of current drug abuse (including analgesic abuse) or alcohol abuse within the last 6 months prior to Screening
- Use of an investigational drug for condition other than MS within 30 days or five half-lives (whichever is longer) preceding Screening. Prior use of an investigational drug for MS should be discussed with the GSK medical monitor
- Any concurrent illness, disability or clinically significant abnormality (including laboratory tests) that may affect the interpretation of clinical efficacy or safety data or prevent the subject from safely completing the assessments required by the protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Arm 1
placebo (4 tablets)
|
placebo tablet
|
Experimental: Arm 2
SB-683699 150 mg bid (1 x 150mg + 3 placebo tablets)
|
placebo tablet
150 mg tablet
Other Names:
|
Experimental: Arm 3
SB-683699 600 mg bid (2 x 300mg + 2 placebo tablets)
|
placebo tablet
300 mg tablet
Other Names:
|
Experimental: Arm 4
SB-683699 900 mg bid (3 x 300 mg + 1 placebo tablet)
|
placebo tablet
300 mg tablet
Other Names:
|
Experimental: Arm 5
SB-683699 1200 mg bid, male subjects only (4 x 300 mg tablets)
|
300 mg tablet
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cumulative number of new gadolinium-enhancing lesions on monthly MRI scans during the Treatment Phase
Time Frame: Baseline and 24 weeks
|
Baseline and 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cumulative volume of new gadolinium-enhancing lesions on monthly MRI scans
Time Frame: Baseline and 24 weeks
|
Baseline and 24 weeks
|
Cumulative number of persistent gadolinium-enhancing lesions on monthly MRI scans
Time Frame: Baseline and 24 weeks
|
Baseline and 24 weeks
|
Cumulative number of total enhancing lesions on monthly MRI scans: the sum of new and persistent gadolinium-enhancing lesions
Time Frame: Baseline and 24 weeks
|
Baseline and 24 weeks
|
Cumulative number of new T1 hypointense lesions on MRI scans
Time Frame: Baseline and 24 weeks
|
Baseline and 24 weeks
|
Cumulative number of new/newly enlarging T2 lesions on MRI scans
Time Frame: Baseline and 24 weeks
|
Baseline and 24 weeks
|
Relapses Occurring during the On-Treatment Phase
Time Frame: Baseline and 24 weeks
|
Baseline and 24 weeks
|
Change from Baseline in Expanded Disability Status Scale (EDSS) scores
Time Frame: Baseline and 24 weeks
|
Baseline and 24 weeks
|
Change from Baseline in Multiple Sclerosis Functional Composite (MSFC)scores
Time Frame: Baseline and 24 weeks
|
Baseline and 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2006
Primary Completion (Actual)
August 1, 2009
Study Completion (Actual)
August 1, 2010
Study Registration Dates
First Submitted
November 1, 2006
First Submitted That Met QC Criteria
November 1, 2006
First Posted (Estimate)
November 2, 2006
Study Record Updates
Last Update Posted (Estimate)
April 9, 2012
Last Update Submitted That Met QC Criteria
April 5, 2012
Last Verified
April 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A4M105038
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Brigham and Women's HospitalMassachusetts General HospitalRecruitingMultiple Sclerosis | Relapsing Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
University of MinnesotaMallinckrodtTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States